Latest Regulatory Risk News

Meteoric Resources has successfully commissioned its Mixed Rare Earth Carbonate pilot plant in Brazil, achieving strong recovery rates and production outputs that validate its processing approach and de-risk the Caldeira project.

DPM Metals Inc. delivered record revenues and earnings in 2025, driven by higher metal prices and stable production, while completing the strategic acquisition of Adriatic Metals plc, adding the Vareš polymetallic mine to its portfolio. The company outlines a robust three-year growth plan focused on expanding production and exploration.

Arena REIT reported a remarkable 202% jump in net profit for the half-year ending December 2025, driven by significant property revaluation gains and steady rental income growth. Distributions rose 5%, supported by an expanded and fully leased portfolio of early learning and healthcare properties.

Evolution Energy Minerals Limited has announced a renounceable pro-rata entitlement offer to raise up to $4.03 million, aiming to fund exploration and development of its Tanzanian copper and graphite assets. The offer includes free attaching options and is partially underwritten, reflecting both opportunity and risk amid regulatory challenges.

Commonwealth Bank of Australia reported a 5% increase in statutory net profit after tax to $5.367 billion for the half year ended December 2025, supported by lending growth and improved credit quality despite margin pressures and higher expenses. The bank declared a fully franked interim dividend of $2.35 per share.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Beach Energy reported a resilient first half of FY26, overcoming Cooper Basin floods to deliver solid earnings boosted by LNG cargoes and higher gas prices. The company’s operational safety and environmental efforts underpin a confident outlook as key projects ramp up.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Island Pharmaceuticals secures FDA confirmation on Galidesivir’s development under the Animal Rule, unlocking a streamlined two-stage approval process and significant commercial incentives.

Argenica Therapeutics has won a crucial regulatory waiver from the European Medicines Agency, removing the need for paediatric trials for its stroke drug ARG-007 and clearing the way for faster adult market approval in Europe.